Postmenopausal unopposed estrogen and estrogen plus progestin use and risk of non-Hodgkin lymphoma in the American Cancer Society Cancer Prevention Study-II Cohort

Leukemia and Lymphoma

Volumn 54, Issue 4, 2013, Pages 720-725

  Teras, Lauren R ^a   Patel, Alpa V ^a   Hildebrand, Janet S ^a   Gapstur, Susan M ^a  

^a AMERICAN CANCER SOCIETY   (United States)

Author keywords

Cohort; Estrogen; Estrogen plus progestin; Multiple myeloma; Non Hodgkin lymphoma; Postmenopausal hormone use

Indexed keywords

ESTROGEN; GESTAGEN; ORAL CONTRACEPTIVE AGENT; PROGESTERONE;

ADULT; AGED; ARTICLE; CANCER PREVENTION; CHRONIC LYMPHATIC LEUKEMIA; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HAZARD RATIO; HIGH RISK POPULATION; HORMONE SUBSTITUTION; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MEDICAL SOCIETY; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; ORAL CONTRACEPTION; POSTMENOPAUSE; PRIORITY JOURNAL; SMOKING;

AGED; ESTROGENS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; POSTMENOPAUSE; PROGESTINS; PROSPECTIVE STUDIES; RISK; UNITED STATES;

EID: 84879517601     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.722216     Document Type: Article

References (33)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2 010. C A Cancer J Clin 2010; 60 :277-300.
2. Turner JJ, Morton LM, Linet MS, et al. InterLymph hierarchical classifi cation of lymphoid neoplasms for epidemiologic research based on the WHO classifi cation (2008): Update and future directions. Blood 2010; 116: E90-e98.
3. Grulich AE, Vajdic CM. The epidemiology of non-Hodgkin lymphoma. Pathology 2005; 37: 409-419.
4. Bouman A, Heineman MJ, Faas MM. Sex hormones and the immune response in humans. Hum Reprod Update 2005; 11: 411-423.
5. Ahmed SA, Talal N. Sex hormones and the immune system -Part 2. Animal data. Baillieres Clin Rheumatol 1990; 4: 13-31.
6. Li JJ. Perspectives in hormonal carcinogenesis: Animal models to human disease. Prog Clin Biol Res 1996; 394: 447-454.
7. Taylor H S, Manson J E. U pdate in hormone therapy use in menopause. J Clin Endocrinol Metab 2011; 96: 255-264.
8. Norgaard M, Poulsen AH, Pedersen L, et al. Use of postmenopausal hormone replacement therapy and risk of non-Hodgkin's lymphoma: A Danish population-based cohort study. Br J Cancer 2006; 94: 1339-1341.
9. Mildon K H, Ansell P, Roman E, et al. Reproductive factors, menopausal hormone therapy, and risk of non-Hodgkin, Diffuse large B-cell and follicular lymphomas: A UK case-control study. Cancer Causes Control 2010; 21: 2079-2083.
10. Lee JS, Bracci PM, Holly EA. Non-Hodgkin lymphoma in women: Reproductive factors and exogenous hormone use. Am J Epidemiol 2008; 168: 278-288.
11. Altieri A, Gallus S, Franceschi S, et al. Hormone replacement therapy and risk of lymphomas and myelomas. Eur J Cancer Prev 2004; 13: 349-351.
12. Fernandez E, Gallus S, Bosetti C, et al. Hormone replacement therapy and cancer risk: A systematic analysis from a network of casecontrol studies. Int J Cancer 2003; 105: 408-412.
13. Landgren O, Zhang Y, Zahm S H, et al. Risk of multiple myeloma following medication use and medical conditions: A case-control study in Connecticut women. Cancer Epidemiol Biomarkers Prev 2006; 15: 2342-2347.
14. Morton L M, Wang S S, Richesson D A, et al. Reproductive factors, exogenous hormone use and risk of lymphoid neoplasms among women in the National Institutes of Health-AARP Diet and Health Study Cohort. Int J Cancer 2009; 124: 2737-2743.
15. Beiderbeck AB, Holly EA, Sturkenboom MC, et al. No increased risk of non-Hodgkin's lymphoma with steroids, estrogens and psychotropics (Netherlands). Cancer Causes Control 2003; 14: 639-644.
16. Nelson R A, Levine A M, Bernstein L. R eproductive factors and risk of intermediate-or high-grade B-Cell non-Hodgkin's lymphoma in women. J Clin Oncol 2001; 19: 1381-1387.
17. Zhang Y, Holford TR, Leaderer B, et al. Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut United States women. Cancer Causes Control 2004; 15: 419-428.
18. Cerhan JR, Vachon CM, Habermann TM, et al. Hormone replacement therapy and risk of non-Hodgkin lymphoma and chronic lymphocytic leukemia. Cancer Epidemiol Biomarkers Prev 2002; 11: 1466-1471.
19. Lu Y, Wang SS, Sullivan-Halley J, et al. Oral contraceptives, menopausal hormone therapy use and risk of B-cell non-Hodgkin lymphoma in the California Teachers Study. Int J Cancer 2011; 129: 974-982.
20. Calle EE, Rodriguez C, Jacobs EJ, et al. The American Cancer Society Cancer Prevention Study II Nutrition Cohort: Rationale, study design, and baseline characteristics. Cancer 2002; 94: 2490-2501.
21. Swerdlow S, Campo E, Harris N. World Health Organization classifi cation of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Pres s; 2008.
22. Th erneau TM, Grambsch PM. Modeling survival data: Extending the Cox model. New York: Springe r; 2000.
23. Cochran WG. The combination of estimates from diff erent experiments. Biometrics 1954; 10: 101-129.
24. Folsom AR, Mink PJ, Sellers TA, et al. Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women. Am J Public Health 1995; 85: 1128-1132.
25. Stefanick M L. E strogens and progestins: Background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration. Am J Med 2005; 118(Suppl. 12B):64-73.
26. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefi ts of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women ' s Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333.
27. Gaikwad NW, Yang L, Weisenburger DD, et al. Urinary biomarkers suggest that estrogen-DNA adducts may play a role in the aetiology of non-Hodgkin lymphoma. Biomarkers 2009; 14: 502-512.
28. Chakravarti D, Zahid M, Backora M, et al. Ortho-quinones of benzene and estrogens induce hyperproliferation of human peripheral blood mononuclear cells. Leuk Lymphoma 2006; 47: 2635-2644.
29. Lu F, Zahid M, Saeed M, et al. Estrogen metabolism and formation of estrogen-DNA adducts in estradiol-treated MCF-10F cells. The Effects of 2, 3, 7,8-tetrachlorodibenzo-p-dioxin induction and catecho l-O-methyltransferase inhibition. J Steroid Biochem Mol Biol 2007 ;105:150-158.
30. Yasui T, Uemura H, Tezuka M, et al. Biological Effects of hormone replacement therapy in relation to serum estradiol levels. Horm Res 2001; 56: 38-44.
31. Lang TJ. Estrogen as an immunomodulator. Clin Immunol 2004; 113: 224-230.
32. Kincade PW, Medina KL, Payne KJ, et al. Early B-lymphocyte precursors and their regulation by sex steroids. Immunol Rev 2000; 175: 128-137.
33. Forsberg JG. Short-term and long-term Effects of estrogen on lymphoid tissues and lymphoid cells with some remarks on the signifi cance for carcinogenesis. Arch Toxicol 1984; 55: 79-90.